ReviewArchives of Razi Institute2025
Immunomodulatory Functions of Mesenchymal Stem Cells in Tissue Engineering.
Review in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Innovative strategies for immune thrombocytopenia treatment: immunomodulatory mechanisms and clinical potential of mesenchymal stem cells.Stem cell research & therapy · 2026Review
- Combined Stromal Vascular Fraction and HGF-Functionalized Self-Assembling Peptide Hydrogel Improves Intracerebral Hemorrhage Repair in Rats.Gels (Basel, Switzerland) · 2026Article
- Cellular stress, cell death, and extracellular vesicles: redefining the therapeutic landscape of rheumatoid arthritis.Clinical rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) have been demonstrated to exhibit immunomodulatory properties, thereby modulating the immune response and facilitating tissue regeneration. These properties include the ability to suppress T cell proliferation, modulate macrophage polarization, and promote regulatory T cell differentiation. It has been demonstrated that natural chemoattraction pathways can attract MSCs. These cells are created from around the injured tissues, creating a repair/regenerative microenvironment for this study. The rate of tissue regeneration is contingent upon factors such as the patient's age, the extent of tissue damage, and the specific anatomical region affected. It has been demonstrated that the manipulation of mesenchymal stem cells can exert a substantial influence on the rate of tissue damage, tissue regeneration, and cell death. The immunosuppressive and trophic mechanisms under investigation are distinct from the mechanisms that are being led by tissue engineering to replace special mesenchymal tissues. Indeed, the capacity of tissue engineering processes to facilitate trophic interactions is evident, thereby promoting remarkable tissue regeneration and ensuring the seamless incorporation of newly generated tissue into the body. The field of MSCs has been a subject of study for over two decades, and recent advancements have begun to unlock their full potential for clinical applications. It is evident that the utilization of MSCs in tissue engineering necessitates distinct rationale when compared to their application in nutritional and immunomodulatory functions. These latter efforts now appear to apply to the clinic before tissue engineering methods become feasible. The findings of this study demonstrate that MSCs possess the capacity to differentiate into various cell types, which renders them a suitable candidate for treating a wide range of human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.